Clinical Trials in Salt Lake City

Showing 11721-11740 of 14,325 trials

Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation

NCT01546883

This study includes treating patients with atrial fibrillation (AF) with Dabigatran, an anti-coagulant for a period of one year to see if there are any significant changes in the degree of left atrial structural remodeling in these patients. The investigators hypothesize that there will be a significant decrease in the degree of left atrial structural remodeling (fibrosis) in AF patients treated with dabigatran.

Atrial Fibrillation

University of Utah14 participantsStarted Feb 2012

Salt Lake City, Utah, United States

COMPLETEDPhase 3< 1 mile

A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain

NCT01539538

The study is intended to show that the Sufentanil NanoTab PCA System is as effective as morphine intravenous patient-controlled analgesia (IV PCA) for treating pain after surgery. Each patient will use either the Sufentanil NanoTab PCA System or morphine IV PCA to treat their pain for at least 48 hours and up to 72 hours after surgery while in the hospital.

Post-Operative Pain

Talphera, Inc357 participantsStarted Apr 2012

Florence, Alabama, United States • Montgomery, Alabama, United States • Sheffield, Alabama, United States +13 more locations

Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation

A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain

Find Trials by Condition in Salt Lake City

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

PoC in Rheumatoid Arthritis With Methotrexate

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

Burn Outcomes in Young Adult Burn Survivors

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

Phase II, 2nd Line Melanoma - RAND Monotherapy

A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Ph IIA Study (SOC +/- NS5B)

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types